Building a Faster, More Flexible Biologic Development Process for Targeted Therapies

Jul 31, 2018

Register Free: http://www.pharmtech.com/pt_w/building

With the dramatic rise in the number of precision medicines and orphan drug designations in development—many of which are biologics—many companies are racing furiously to get these precious and expensive molecules to clinic as quickly as possible. Speed, small batch sizes, material losses, and economics are all major concerns for companies attempting to accelerate their molecule through early development.                                                                                         

Learn how these shifting therapeutic trends have increased the need for fast, flexible development and these solutions that are helping companies overcome these challenges:

  • Fast, flexible options for mammalian cell line development and process development
  • Advantages of integrated drug substance, drug product, and clinical trial logistics solutions
  • Selecting the right dosage form
  • Benefits of having the right-sized filling lines that are appropriate for early development

 

Key Learning Objectives:

During this webcast, participants will learn:  

  1. Factors behind the dramatic rise in targeted therapies in development
  2. Challenges executives at small biopharma companies face getting to first-in-human trials
  3. Solutions that small biopharma companies are leveraging to get to clinic quickly

 

Speakers:

David J. Kenyon, PhD, Sr. Director, Scientific and Technical Affairs, Pharma Services, Patheon, part of Thermo Fisher Scientific

Tony Pidgeon, Process Technology Director, Patheon, part of Thermo Fisher Scientific

 

Date and Time:

Live: Tuesday, 31 July, 2018 at 10 am EDT | 1500 BST | 1600 CEST

After the final airing of the webcast on 31 July, 2018 it will be available on demand until 31 July, 2019. 

Sponsor: Patheon, part of Thermo Fisher Scientific

Register Free: http://www.pharmtech.com/pt_w/building   

native1_300x100
lorem ipsum